LYME DISEASE, CLASSIFICATION AND CODES II.
ENFERMEDAD DE LYME, CLASIFICACION Y CODIGOS II.
EDITORIAL ENGLISH
==================
Hello friends of the network I hope that very well, this Christmas DERMAGIC EXPRESS brings you the second chapter of THE CODES OF LYME DISEASE. In the previous review I said that some details were missing that I was going to clarify in another edition that I am preparing and that was titled LYME, SYPHILIS AND LEPROSY, THE MISSING LINK, but I knew that the CLASSIFICATION AND CODES OF LYME were INCOMPLETE, and today I will put here.
I had said that CODES at the DIGITAL or SOFTWARE level are based on a classification and that this is done in terms of the clinical presentation of the disease and REPORTS, PUBLICATIONS and SCIENTIFIC INVESTIGATIONS; and that the World Health Organization (WHO) is TOTALLY out of date regarding this and THEREFORE there is not enough coverage of the LYME DISEASE AND ITS MULTIPLE CLINICAL MANIFESTATIONS, COMPLICATIONS and SYMPTOMS derived from the permanence of the SPIROCHETE BORRELIA In the body, the bases that support these facts are:
1.) DIFFICULTY TO MAKE THE DIAGNOSIS:
2.) RESISTANCE TO CONVENTIONAL TREATMENT:
3.) THE LACK OF MODERNIZATION OF THE CODES FOR THE LYME DISEASE.
And today I bring you other BIBLIOGRAPHIC REFERENCES that would complete a CLASSIFICATION that in my view would FULLY ENLARGE assistance to THOUSANDS OF PATIENTS carrying LYME that simply do not "APPEAR IN THE SYSTEM" because the CODES do not exist. Today I add a 4th and 5th aspect:
4.) LYME DISEASE AND HISTOCOMPATIBILITY ANTIGENS: (HLA)
===================================================
It is noteworthy in these data that today I will place, that the MAJOR HISTOCOMPATIBILITY SYSTEM (HLA) is HIGHLY involved in the LYME DISEASE, specifically the patients carrying the HLA DR molecules, it is even said that the presence of these molecules or ALLELES are involved in the pathogenicity of this disease and the triggering of AUTOIMMUNE DISEASES. In fact, there are studies showing the RESISTANCE TO SOME ANTIBIOTICS in relation to these HLA molecules.
There are HLA molecules that confer RESISTANCE TO THE DISEASE and OTHERS SUSCEPTIBILITY to the treatment, this would facilitate even more the behavior to follow with the patients; and I finish with this:
"... ALL PATIENT CARRIER OF LYME HAS TO HAVE A STUDY OF HISTOCOMPATIBILITY (HLA) ANTIGENS ..."
5.) LYME DISEASE AND GEOGRAPHICAL DISTRIBUTION:
===============================================
It is well known that the BORRELIA BURGDORFERI and its multiple SPECIES in the terrestrial globe, ARE DIFFERENT AS TO GEOGRAPHY, both in EUROPE and AMERICA. Well, I also tell you that there are studies showing that THE SPECIES OF BORRELIA in some ZONES such as EUROPE are sensitive to certain antibiotics, which in other areas of the continent show resistance, so that the GEOGRAPHICAL DISTRIBUTION AND SPECIES OF THE BORRELIA SPIROCHETE must be included in THE CODES.
6.) LYME DISEASE AND OPTICAL MICROSCOPY:
==========================================
The BORRELIA is an SPIROCHETE like the SYPHILIS, and the METHOD STANDART to detect the SYPHILIS IS OPTICAL MICROSCOPY, "DARK FIELD", then appeared other more sophisticated methods such as the VDRL and others. In the case of the BORRELIA, in the year 2.013 the professors LAANE and MYSTERUD, invented a simple method based on the fact that the BORRELIA, like the SYPHILIS TREPONEMA, could be "DETECTED" by means of a SIMPLE OPTICAL MICROSCOPE and that's how it was. They published the work (ref. 320), but were later discredited and dismissed by the scientific society including the CDC, claiming that the most effective methods were the laboratory ones, and today YET, many of the tests for LYME are negative and the BORRELIA "NAVIGATE" in the blood of patients. There I leave you the photo of BORRELIA AND BIOFILM and Professor LAANE.
If you read the previous review the CLASSIFICATION had been in the point No. 15: and here I put the continuation, it is important that you read the previous revision so that you can understand: THE CODES OF THE LYME DISEASE. CLICK here
15.) LYME LATENT DISEASE: UNSPECIFIED SYMPTOMS.
A.) INFECTION OF THE CENTRAL NERVOUS SYSTEM.
B.) HERPES SIMPLEX TYPE 1.
C.) DISEASES BY SPIROCHETES OF THE CENTRAL NERVOUS SYSTEM.
--- CONTINUATION--
16.) LYME DISEASE LATE STAGE: SYNDROME POST TREATMENT (PTLDS):
A.) FATIGUE.
B.) ARTHRALGIA.
C.) FIBROMYALGIA, MYALGIA.
D.) RADICULAR PAIN.
E.) MUSCULOSKELETAL PAIN.
F.) COGNITIVE DYSFUNTICON:
- DECREASED MEMORY.
- CONCETRATION PROBLEMS.
G.) PSYCHIATRICS CONDITIONS:
- DEPRESSION.
- SUICIDAL IDEATION.
- DEMENTIA.
H.) FACIAL PALSY.
I.) AUTOIMMUNE DISORDERS.
17.) LYME DISEASE ASSOCIATED TO OTHER DISEASES:
A.) MULTIPLE SCLEROSIS.
B.) PARKINSON.
C.) AUTOINMMUNE DISORDERS:
- REUMATOID ARTHRITIS.
- PSORIRIATIC ARTHRITIS.
- PERIPHERAL SPONDYLOARTHRITIS.
- POLYARTHRITIS.
18.) LYME DISEASE AND HLA (MAJOR SYSTEM OF HISTOCOMPATIBILITY) TRIGGER OTHER DISEASES:
A.) LYME ARTHRITIS: HLA-DRB1, (DRB1*0401, 0101, 0404, 0405, DRB5*0101, DRB1*0402, and 0102), DR11, DR4
19.) LYME DISEASE AND HLA DRB ANTIGENS (MAJOR SYSTEM OF HISTOCOMPATIBILITY) IS A MARKER FOR ANTIBIOTIC- REFRACTORY TRATMENT- and migth play a role in the pathogenesis os the disease.
A.) LYME ARTHRITIS.
20.) LYME DISEASE GEOGRAPHIC DISYTIBUTIONS, SPECIES OF BORRELIA LEADS TO ANTIBIOTICS SUSCESPTIBILITY.
A.) EUROPEAN LYME NEUROBORRELIOSIS: SUSCEPTIBILITY TO DOXYCYCLINE, PENICILLIN G, CEFTRIAXONE AND CEFOTAXIME.
21.) LYME DISEASE EARLY AND DELAYED JARISCH -HERXHEIMER REACCTION TO ANTIBIOTICS
A.) AMOXICILIN.
B.) DOXYCYCLINE.
C.) CEFTRIAXONE
22.) LYME DISEASE, SECUNDARY OR LATE STAGE: RESISTANT TO ANTIBIOTICS,
A.) DOXYCYCLINE.
B.) MINOCYCLINE.
C.) CEFTRIAXONE.
D.) AMOXICILIN.
E.) MITOMYCIN C.
F.) CEFUROXIME.
G.) DOXORUBICIN.
23.) LYME DISEASE AND NATURIST HERBS: oregano, cinnamon bark, and clove improve the disease.
24.) LYME DISEASE SUSCEPIBILITY TO COMBINED ANTIBIOTICS:
A.) DAPSONE + MINOCYCLINE+ CEFUROXIME+ AZYTHROMYCIN
B.) DAPSONE + MINOCYCLINE+ CEFUROXIME+ RIFAMPICIN
C.) DAPTOMYCIN + DOXYCYCLINE+ CEFUROXIME
D.) DAUNOMYCIN + DOXYCYLINE + CEFUROXIME
E.) DAPTOMYCIN+ CEFOPERAZONE+ DOXYCYCLINE.
F.) DAPTOMYCIN+ DOXYCYCLINE+ CLOFAZIMINE
G.) DATPOMICYN + (CEFOPERAZONE OR CARBENICILLIN)+ CLOFAZIMINE
I will remind you that the options DAPSONE + MINOCYCLINE + RIFAMPICIN and DAPSONE + CLOFAZIMINE + RIFAMPICIN are today classic treatments used in LEPROSY for more than 60 years and through which they have managed to reduce the incidence of this disease in the world today.
Practically the arrival of this TRIAD = DAPSONE + RIFAMPICIN + CLOFAZIMINE, in the 40s -50s years was the one who decreed the FINAL CLOSURE of the LEPROSERIES in the WORLD, read the stories here:
- THE LEPROSY IN CAPE WHITE. Clik Here
- LEPROSY ON THE ISLAND OF PROVIDENCIA. Click here
And as I told you before, do not miss the next issue of LYME, SYPHILIS AND LEPROSY, THE MISSING LINK.
Finally, I would like all the organizations and communities that fight against the LYME DISEASE, to send this CLASSIFICATION, CODES and BIBLIOGRAPHICAL REFERENCES to the World Health Organization (WHO), so that they can be updated regarding the serious problem that this disease represents in all the PLANET and that has been neglected for being aware of other health problems, much smaller, thinking perhaps that everything related to the word LYME, is an optical illusion that blinds them to such a severe problem.
Greetings to all.
Dr Jose Lapenta
"... Dedicated to all those LYME CARRIERS that society has forgotten ...or are in the oblivion..."
EDITORIAL ESPAÑOL
==================
Hola amigos de la red espero que muy bien en estas Navidades DERMAGIC EXPRESS les trae el segundo capítulo de LOS CODIGOS DE LA ENFERMEDAD DE LYME. En La revisión previa dije que faltaban algunos detalles que iba a aclarar en otra edición que ya estoy preparando y que se titulara LYME, SIFILIS Y LEPRA, EL ESLABON PERDIDO, pero sabía que la CLASIFICACION Y LOS CODIGOS DE LYME estaban INCOMPLETOS, y hoy te los pongo acá.
Había dicho que los CODIGOS a nivel DIGITAL o SOFTWARE están basados en una clasificación y que esta se hace en cuanto a la presentación clínica de la enfermedad y LOS REPORTES, PUBLICACIONES e INVESTIGACIONES CIENTIFICAS; y que la Organización Mundial de La Salud (OMS) , está TOTALMENTE desactualizada en cuanto a ello y POR LO TANTO no hay la suficiente cobertura de la ENFERMEDAD DE LYME Y SUS MULTIPLES MANIFESTACIONES CLINICAS, COMPLICACIONES y SINTOMAS derivados DE LA permanencia de la ESPIROQUETA BORRELIA en el cuerpo, las bases que sostienen estos hechos son:
1.) DIFICULTAD PARA HACER EL DIAGNOSTICO:
2.) RESISTENCIA AL TRATAMIENTO CONVENCIONAL:
3.) LA FALTA DE MODERNIZACION DE LOS CODIGOS PARA LA ENFERMEDAD DE LYME.
Y hoy te traigo otras REFRENCIAS BIBLIOGRAFICAS que completarían una CLASIFICACION que a mi modo de ver AMPLIARIA TOTALMENTE la asistencia a MILES DE PACIENTES portadores de LYME que simplemente no "APARECEN EN EL SISTEMA" pues los CODIGOS no existen. Hoy le agrego un 4to y 5to aspecto:
4.) ENFERMEDAD DE LYME Y ANTIGENOS DE HISTOCOMPATIBILIDAD: (HLA)
===============================================================
Es de resaltar en estos datos que hoy te voy a colocar que el SISTEMA MAYOR DE HISTOCOMPATIBILIDAD (HLA) está ALTAMENTE involucrado en la ENFERMEDAD DE LYME, específicamente los pacientes portadores de las moléculas HLA DR, incluso se habla de que la presencia de estas moléculas o ALELOS están involucrados en la patogenicidad de esta enfermedad y el desencadenamiento de ENFERMEDADES AUTOINMUNES. De hecho hay estudios donde se demuestra LA RESISTENCIA A ALGUNOS ANTIBIOTICOS en relación a estas moléculas HLA.
Hay moléculas HLA que confieren RESISTENCIA A LA ENFERMEDAD y OTRAS SUSCEPTIBILIDAD al tratamiento, esto facilitaría aun más la conducta a seguir con los pacientes; y finalizo con esto:
"...TODO PACIENTE PORTADOR DE LYME TIENE QUE TENER UN ESTUDIO DE ANTIGENOS DE HISTOCOMPATIBILIDAD (HLA)..."
5.) ENFERMEDAD DE LYME Y DISTRIBUCION GEOGRAFICA:
================================================
Bien es sabido que la BORRELIA BURDORGFERI y sus múltiples ESPECIES en el globo terráqueo, SON DIFERENTES EN CUANTO A LA GEOGRAFIA, tanto en EUROPA como AMERICA. Pues también te digo que hay estudios donde se demuestra que LAS ESPECIES DE BORRELIA en algunas ZONAS como EUROPA son sensibles a determinados antibióticos, donde en otras áreas del continente muestran resistencia, DE MODO que la DISTRIBUCION GEOGRAFICA Y ESPECIES DE LA ESPIROQUETA BORRELIA deben FIGURAR EN LOS CODIGOS.
6.) ENFERMEDAD DE LYME Y MICROSCOPIA OPTICA:
============================================
La BORRELIA es una ESPIROQUETA al igual que la SIFILIS, y el METODO ESTANDART para detectar la SIFILIS ES LA MICROSCOPIA OPTICA, "CAMPO OSCURO", luego aparecieron otros métodos más sofisticados como el VDRL y otros más. En el caso de la BORRELIA, en el año 2.013 los profesores LAANE y MYSTERUD, idearon un método sencillo basado en el hecho de que la BORRELIA al igual que la SIFILIS, TREPONEMA podía "DETECTARSE" por medio de una SIMPLE MICROSCOPIA OPTICA y así fue. Publicaron el trabajo (ref. 320), pero fueron posteriormente desacreditados y desechados por la sociedad científica incluyendo el CDC, alegando que los métodos más eficaces eran los de laboratorio, y hoy día TODAVIA, muchas de las pruebas para LYME dan negativo y la BORRELIA "NAVEGA" en la sangre de los pacientes. Allí les dejo la foto de la BORRELIA Y BIOFILM y el profesor LAANE.
Si lees la revisión previa la CLASIFICACION había quedado en el punto No. 15: y acá te pongo la continuación, es importante que leas la revisión previa para que puedas entender: LOS CODIGOS DE LA ENFERMEDAD DE LYME. Click aqui
15.) ENFERMEDAD DE LYME LATENTE: SINTOMAS INESPECIFICOS.
A.) INFECCION DEL SISTEMA NERVIOSO CENTRAL.
B.) HERPES SIMPLE TIPO 1.
C.) ENFERMEDADES POR ESPIROQUETAS DEL SISTEMA NERVIOSO CENTRAL.
- CONTINUACION -
16.) ENFERMEDAD DE LYME, ETAPA TARDIA: SÍNDROME POST TRATAMIENTO (PTLDS):
A.) FATIGA.
B.) ARTRALGIA.
C.) FIBROMIALGIA, MIALGIA.
D.) DOLOR RADICULAR.
E.) DOLOR MUSCULOESQUELÉTICO.
F.) DISFUNTICON COGNITIVA:
- DISMINUCIÓN DE LA MEMORIA
- PROBLEMAS DE CONCENTRACIÓN.
G.) CONDICIONES DE PSIQUIATRICAS:
- DEPRESIÓN.
- IDEACIÓN SUICIDA.
- DEMENCIA.
H.) PARÁLISIS FACIAL.
I.) TRASTORNOS AUTOINMUNES.
17.) ENFERMEDAD DE LYME ASOCIADA A OTRAS ENFERMEDADES:
A.) ESCLEROSIS MÚLTIPLE.
B.) PARKINSON.
C.) TRASTORNOS AUTOINMUNES:
- ARTRITIS REUMATOIDE.
- ARTRITIS PSORIÁTICA.
- ESPONDILOARTRITIS PERIFÉRICA.
- POLIARTRITIS.
18.) ENFERMEDAD DE LYME Y HLA (SISTEMA MAYOR DE HISTOCOMPATIBILIDAD) DESENCADENAN OTRAS ENFERMEDADES:
A.) ARTRITIS DE LYME: HLA-DRB1, (DRB1 * 0401, 0101, 0404, 0405, DRB5 * 0101, DRB1 * 0402 y 0102), DR11, DR4
19.) ENFERMEDAD LYME Y LOS ANTÍGENOS HLA DR-B (SISTEMA MAYOR DE HISTOCOMPATIBILIDAD) ES UN MARCADOR PARA TRATAMIENTO ANTIBIÓTICO-REFRACTARIO, y pueden desempeñar un papel en la patogénesis de la enfermedad.
A.) LYME ARTRITIS.
20.) ENFERMEDAD DE LYME Y DISTRIBUCION GEOGRÁFICAS DE LAS ESPECIES DE BORRELIA Y SUSCEPTIBILIDAD A ANTIBIÓTICOS.
A.) NEUROBORRELIOSIS DE LYME EN EUROPA: SUSCEPTIBILIDAD A LA DOXICICLINA, PENICILINA G, CEFTRIAXONA Y CEFOTAXIMA.
21.) ENFERMEDAD DE LYME: REACCIÓN DE JARISCH - HERXHEIMER TEMPRANA Y TARDIA A ANTIBIÓTICOS
A.) AMOXICILINA.
B.) DOXICICLINA
C.) CEFTRIAXONA.
22.) ENFERMEDAD DE LYME, ETAPA SECUNDARIA O TARDÍA: RESISTENTE A LOS ANTIBIÓTICOS,
A.) DOXICICLINA.
B.) MINOCICLINA.
C.) CEFTRIAXONA.
D.) AMOXICILINA.
E.) MITOMICINA C.
F.) CEFUROXIMA.
G.) DOXORUBICINA.
23.) ENFERMEDAD DE LYME Y HIERBAS NATURISTAS: el orégano, la corteza de canela y el clavo mejoran la enfermedad.
24.) ENFERMEDAD LYME Y SUSCEPTIBILIDAD A ANTIBIÓTICOS COMBINADOS:
A.) DAPSONA + MINOCICLINA + CEFUROXIMA + AZYTROMICINA
B.) DAPSONA + MINOCICLINA + CEFUROXIMA + RIFAMPICINA
C.) DAPTOMICINA + DOXICICLINA + CEFUROXIMA
D.) DAUNOMICINA + DOXICICLINA + CEFUROXIMA
E.) DAPTOMICINA + CEFOPERAZONA + DOXICICLINA.
F.) DAPTOMICINA + DOXICICLINA + CLOFAZIMINE
G.) DATPOMICINA + (CEFOPERAZONA O CARBENICILINA) + CLOFAZIMINE
Les voy a recordar que las opciones DAPSONA + MINOCICLINA + RIFAMPICINA y DAPSONA + CLOFAZIMINE + RIFAMPICINA son hoy tratamientos clásicos utilizados en la LEPRA durante más de 60 años y que han logrado reducir la incidencia de esta enfermedad en el mundo hoy día.
Prácticamente la llegada de esta TRIADA= DAPSONA+ RIFAMPICINA+ CLOFAZIMINE, en los años 40-50 fue quien decreto el CIERRE DEFINITIVO de las LEPROSERIAS en el MUNDO, léase las historias aquí:
- LA LEPRA EN CABO BLANCO. Click aqui
- LEPRA EN LA ISLA DE PROVIDENCIA. Click aqui
Y como te dije anteriormente no te pierdas la próxima edición LYME, SIFILIS Y LEPRA, EL ESLABON PERDIDO.
Por ultimo quisiera que todas las organizaciones y comunidades que luchan contra LA ENFERMEDA DE LYME, envien esta CLASIFICACION, CODIGOS Y REFERENCIAS BIBLIOGRAFICAS a la Organizacion Mundial de la Salud (OMS), para que se actualicen en cuanto al grave problema que representa esta enfermedad en todo el PLANETA y que ha sido descuidada por estar pendientes de otros problemas de salud, mucho menores, pensando quiza que todo lo relacionado con la palabra LYME, es una ilusion optica que les ciega la vista a tan severo problema.
Saludos a Todos
Dr. José Lapenta
"...Dedicado a todos aquellos PORTADORES DE LYME que la sociedad tiene en el olvido...."
=========================================================
REFERENCIAS BIBLIOGRAFICAS / BIBLIOGRAPHICAL REFERENCES
=========================================================
282.) Effects of intravenous ketamine in a patient with post-treatment Lyme disease syndrome. Int Med Case Rep J. 2017 Aug 18;10:305-308. doi: 10.2147/IMCRJ.S137975. eCollection 2017. [PUBMED] Hanna AF1, Abraham B1, Hanna A1, Smith AJ1.
283.) Update of the Swiss guidelines on post-treatment Lyme disease syndrome. Swiss Med Wkly. 2016 Dec 5;146:w14353. doi: 10.4414/smw.2016.14353. eCollection 2016. [PUBMED] Nemeth J1, Bernasconi E2, Heininger U3, Abbas M4, Nadal D5, Strahm C6, Erb S7, Zimmerli S8, Furrer H8, Delaloye J9, Kuntzer T10, Altpeter E11, Sturzenegger M12, Weber R1,
284.) Lyme disease and post-treatment Lyme disease syndrome: the neglected disease in our own backyard.Public Health. 2014 Sep;128(9):784-91. doi: 10.1016/j.puhe.2014.06.016. Epub 2014 Sep 9. [PUBMED]
285.) Post-Lyme borreliosis syndrome: a meta-analysis of reported symptoms.Int J Epidemiol. 2005 Dec;34(6):1340-5. Epub 2005 Jul 22. [PUBMED] Cairns V1, Godwin J.
286.) Post-Lyme disease syndrome. Reumatologia.2015;53(1):46-8.doi: 10.5114/ reum. 2015.50557. Epub 2015 Apr 10.[PUBMED] Scieszka J1, Dabek J2, Cieslik P1.
287.) Comparison of post-Lyme Borreliosis symptoms in erythema migrans patients with positive and negative Borrelia burgdorferi sensu lato skin culture.Vector Borne Zoonotic Dis. 2011 Jul;11(7):883-9. doi: 10.1089/vbz.2010.0018. Epub 2010 Nov 17. [PUBMED] Stupica D1, Lusa L, Cerar T, Ružic-Sabljic E, Strle F.
288.) Long-term Assessment of Post-Treatment Symptoms in Patients With Culture-Confirmed Early Lyme Disease. Clin Infect Dis. 2015 Dec 15;61(12):1800-6. doi: 10.1093/cid/civ735. Epub 2015 Sep 18. [PUBMED] Weitzner E1, McKenna D1, Nowakowski J1, Scavarda C1, Dornbush R2, Bittker S1, Cooper D1, Nadelman RB1, Visintainer P3, Schwartz I4, Wormser GP1.
289.) Chronic Lyme borreliosis at the root of multiple sclerosis--is a cure with antibiotics attainable? Med Hypotheses. 2005;64(3):438-48. [PUBMED] Fritzsche M1.
290.) The Data as It Is, and the Nature of Neurocognitive Difficulties in Post-Treatment Lyme Disease. Arch Clin Neuropsychol. 2017 Dec 13. doi: 10.1093/arclin/acx121. [Epub ahead of print] [PUBMED] Keilp JG1, Fallon BA2.
291.) Clinical and neurocognitive features of the post Lyme syndrome. J Rheumatol. 1996 Aug;23(8):1392-7. [PUBMED] Bujak DI1, Weinstein A, Dornbush RL.
292.) Terrestrial distribution of the Lyme borreliosis agent Borrelia burgdorferi sensu lato in East Asia. Jpn J Infect Dis. 2004 Dec;57(6):229-35. [PUBMED] Masuzawa T1.
293.) Variable manifestations, diverse seroreactivity and post-treatment persistence in non-human primates exposed to Borrelia burgdorferi by tick feeding. PLoS One. 2017 Dec 13;12(12):e0189071. doi: 10.1371/journal.pone.0189071. eCollection 2017. [PUBMED]
Embers ME1, Hasenkampf NR1, Jacobs MB1, Tardo AC1, Doyle-Meyers LA2, Philipp MT1, Hodzic E3.
294.) Persistence of Borrelia burgdorferi in rhesus macaques following antibiotic treatment of disseminated infection. PLoS One. 2012;7(1):e29914. doi: 10.1371/journal.pone.0029914. Epub 2012 Jan 11. [PUBMED] Embers ME1, Barthold SW, Borda JT, Bowers L, Doyle L, Hodzic E, Jacobs MB, Hasenkampf NR, Martin DS, Narasimhan S, Phillippi-Falkenstein KM, Purcell JE, Ratterree MS, Philipp MT.
295.) Unique expression of chronic Lyme disease and Jarisch-Herxheimer reaction to doxycycline therapy in a young adult. BMJ Case Rep. 2016 Jul 20;2016. pii: bcr2013009433. doi: 10.1136/bcr-2013-009433. [PUBMED] Haney C1, Nahata MC2.
296.) Lyme disease complicated by the Jarisch-Herxheimer reaction. J Emerg Med. 1998 May-Jun;16(3):437-8.[PUBMED] Maloy AL1, Black RD, Segurola RJ Jr.
297.) Delayed onset of the Jarisch-Herxheimer reaction in doxycycline-treated disease: a case report and review of its histopathology and implications for pathogenesis. Am J Dermatopathol. 2015 Jun;37(6):e68-74. doi: 10.1097/DAD.0000000000000093. [PUBMED] Kadam P1, Gregory NA, Zelger B, Carlson JA.
298.) Transient worsening of optic neuropathy as a sequela of the Jarisch-Herxheimer reaction in the treatment of Lyme disease. J Neuroophthalmol. 1994 Jun;14(2):77-80. [PUBMED] Strominger MB1, Slamovits TL, Herskovitz S, Lipton RB.
299.) Successful desensitisation to ceftriaxone in a patient with doxycicline resistant Lyme disease. Erratum in Allergol Immunopathol (Madr). 2009 Jul-Aug;37(4):222.[PUBMED] Rodrigues J, Cruz LG, Botelho C, Rio E, Castel-Branco MG.
300.) Ceftriaxone Pulse Dosing Fails to Eradicate Biofilm-Like Microcolony B. burgdorferi Persisters Which Are Sterilized by Daptomycin/ Doxycycline/Cefuroxime without Pulse Dosing. Front Microbiol. 2016 Nov 4;7:1744. eCollection 2016. [PUBMED] Feng J1, Zhang S1, Shi W1, Zhang Y1.
301.) Antibiotics for the neurological complications of Lyme disease. Cochrane Database Syst Rev. 2016 Dec 8;12:CD006978. doi: 10.1002/14651858.CD006978.pub2. [PUBMED] Cadavid D1, Auwaerter PG2, Rumbaugh J3, Gelderblom H4.
302.) Lyme borreliosis in Slovenia. Zentralbl Bakteriol. 1999 Dec;289(5-7):643-52. [PUBMED] Strle F1.
303.) Immunogenic HLA-DR-Presented Self-Peptides Identified Directly from Clinical Samples of Synovial Tissue, Synovial Fluid, or Peripheral Blood in Patients with Rheumatoid Arthritis or Lyme Arthritis. J Proteome Res. 2017 Jan 6;16(1):122-136. doi: 10.1021/acs.jproteome.6b00386. Epub 2016 Nov 7. [PUBMED] Wang Q1, Drouin EE2, Yao C1, Zhang J1,3, Huang Y1, Leon DR1, Steere AC2, Costello CE1.
304.) Autoimmune Arthritides, Rheumatoid Arthritis, Psoriatic Arthritis, or Peripheral Spondyloarthritis Following Lyme Disease. Arthritis Rheumatol. 2017 Jan;69(1):194-202. doi: 10.1002/art.39866. [PUBMED] Arvikar SL1, Crowley JT1, Sulka KB1, Steere AC1.
305.) T-Helper 17 Cell Cytokine Responses in Lyme Disease Correlate With Borrelia burgdorferi Antibodies During Early Infection and With Autoantibodies Late in the Illness in Patients With Antibiotic-Refractory Lyme Arthritis. Clin Infect Dis. 2017 Apr 1;64(7):930-938. doi: 10.1093/cid/cix002. [PUBMED] Strle K1, Sulka KB1, Pianta A1, Crowley JT1, Arvikar SL1, Anselmo A2, Sadreyev R2, Steere AC1.
306.) Serum reactivity against Borrelia burgdorferi OspA in patients with rheumatoid arthritis. Clin Vaccine Immunol. 2007 Nov;14(11):1437-41. Epub 2007 Sep 19. [PUBMED] Hsieh YF1, Liu HW, Hsu TC, Wei JC, Shih CM, Krause PJ, Tsay GJ.
307.) HLA type and immune response to Borrelia burgdorferi outer surface protein a in people in
whom arthritis developed after Lyme disease vaccination. Arthritis Rheum. 2009 Apr;60(4):1179-86. doi: 10.1002/art.24418.[PUBMED]Ball R1, Shadomy SV, Meyer A, Huber BT, Leffell MS, Zachary A, Belotto M, Hilton E, Bryant-Genevier M, Schriefer ME, Miller FW, Braun MM.
308.) HLA-DR alleles determine responsiveness to Borrelia burgdorferi antigens in a mouse model of self-perpetuating arthritis. Arthritis Rheum. 2009 Dec;60(12):3831-40. doi: 10.1002/art.25005. [PUBMED] Iliopoulou BP1, Guerau-de-Arellano M, Huber BT.
309.) Antibiotic-refractory Lyme arthritis is associated with HLA-DR molecules that bind a Borrelia burgdorferi peptide. J Exp Med. 2006 Apr 17;203(4):961-71. Epub 2006 Apr 3. [PUBMED] Steere AC1, Klitz W, Drouin EE, Falk BA, Kwok WW, Nepom GT, Baxter-Lowe LA.
310.) Association of antibiotic treatment-resistant Lyme arthritis with T cell responses to dominant epitopes of outer surface protein A of Borrelia burgdorferi. Arthritis Rheum. 1999 Sep;42(9):1813-22. [PUBMED] Chen J1, Field JA, Glickstein L, Molloy PJ, Huber BT, Steere AC.
311.) Associations of HLA DR and DQ molecules with Lyme borreliosis in Latvian patients. BMC Res Notes. 2012 Aug 14;5:438. doi: 10.1186/1756-0500-5-438. [PUBMED] Kovalchuka L1, Eglite J, Lucenko I, Zalite M, Viksna L, Krumina A.
312.) Immunogenetic Markers Definition in Latvian Patients with Lyme Borreliosis and Lyme Neuroborreliosis. Int J Environ Res Public Health. 2016 Dec 1;13(12). pii: E1194. [PUBMED] Kovalchuka L1, Cvetkova S2, Trofimova J3, Eglite J4, Gintere S5, Lucenko I6, Oczko-Grzesik B7, Viksna L8, Krumina A9,10.
313.) Serological Evidence of Borrelia Burgdorferi Infection in Mexican Patients with Facial Palsy. Rev Invest Clin. 2017 Nov-Dec;69(6):344-348. doi: 10.24875/RIC.17002344. [PUBMED] Gordillo-Pérez G1, García-Juárez I1, Solórzano-Santos F2, Corrales-Zúñiga L3, Muñoz-Hernández O2, Torres-López J1.
314.) Selective Essential Oils from Spice or Culinary Herbs Have High Activity against Stationary Phase and Biofilm Borrelia burgdorferi. Front Med (Lausanne). 2017 Oct 11;4:169. doi: 10.3389/fmed.2017.00169. eCollection 2017. [PUBMED] Feng J1, Zhang S1, Shi W1, Zubcevik N2, Miklossy J3, Zhang Y1.
315.) Eradication of Biofilm-Like Microcolony Structures of Borrelia burgdorferi by Daunomycin and Daptomycin but not Mitomycin C in Combination with Doxycycline and Cefuroxime. Front Microbiol. 2016 Feb 10;7:62. doi: 10.3389/fmicb.2016.00062. eCollection 2016. [PUBMED] Feng J1, Weitner M1, Shi W1, Zhang S1, Zhang Y1.
316.) Drug combinations against Borrelia burgdorferi persisters in vitro: eradication achieved by using daptomycin, cefoperazone and doxycycline. PLoS One. 2015 Mar 25;10(3):e0117207. doi: 10.1371/journal.pone.0117207. eCollection 2015. [PUBMED] Feng J1, Auwaerter PG2, Zhang Y1.
317.) Activity of Sulfa Drugs and Their Combinations against Stationary Phase B. burgdorferi In Vitro. Antibiotics (Basel). 2017 Mar 22;6(1). pii: E10. doi: 10.3390/antibiotics6010010. [PUBMED] Feng J1, Zhang S2, Shi W3, Zhang Y4.
318.) Lyme neuroborreliosis and dementia. J Alzheimers Dis. 2014;41(4):1087-93. doi: 10.3233/JAD-130446. [PUBMED]Blanc F1, Philippi N1, Cretin B1, Kleitz C2, Berly L2, Jung B1, Kremer S3, Namer IJ4, Sellal F5, Jaulhac B6, de Seze J7.
319.) Distribution and presentation of Lyme borreliosis in Scotland - analysis of data from a national testing laboratory. J R Coll Physicians Edinb. 2015;45(3):196-200. doi: 10.4997/JRCPE.2015.304. [PUBMED] Mavin S1, Watson EJ, Evans R.
320.) A simple method for the detection of live Borrelia spirochaetes in human blood using classical microscopy techniques. Morten Motzfeldt Laane, Ivar Mysterud. Published 2013. Semantic Sholar. Source: https://www.semanticscholar.org/paper/A-simple-method-for-the-detection-of-live-Borrelia-Laane-Mysterud/4f6251e40f196b094905d84e87b8b6fe8d1d1636
Source: https://madisonarealymesupportgroup.com/
==================
Hello friends of the network I hope that very well, this Christmas DERMAGIC EXPRESS brings you the second chapter of THE CODES OF LYME DISEASE. In the previous review I said that some details were missing that I was going to clarify in another edition that I am preparing and that was titled LYME, SYPHILIS AND LEPROSY, THE MISSING LINK, but I knew that the CLASSIFICATION AND CODES OF LYME were INCOMPLETE, and today I will put here.
I had said that CODES at the DIGITAL or SOFTWARE level are based on a classification and that this is done in terms of the clinical presentation of the disease and REPORTS, PUBLICATIONS and SCIENTIFIC INVESTIGATIONS; and that the World Health Organization (WHO) is TOTALLY out of date regarding this and THEREFORE there is not enough coverage of the LYME DISEASE AND ITS MULTIPLE CLINICAL MANIFESTATIONS, COMPLICATIONS and SYMPTOMS derived from the permanence of the SPIROCHETE BORRELIA In the body, the bases that support these facts are:
1.) DIFFICULTY TO MAKE THE DIAGNOSIS:
2.) RESISTANCE TO CONVENTIONAL TREATMENT:
3.) THE LACK OF MODERNIZATION OF THE CODES FOR THE LYME DISEASE.
And today I bring you other BIBLIOGRAPHIC REFERENCES that would complete a CLASSIFICATION that in my view would FULLY ENLARGE assistance to THOUSANDS OF PATIENTS carrying LYME that simply do not "APPEAR IN THE SYSTEM" because the CODES do not exist. Today I add a 4th and 5th aspect:
4.) LYME DISEASE AND HISTOCOMPATIBILITY ANTIGENS: (HLA)
===================================================
It is noteworthy in these data that today I will place, that the MAJOR HISTOCOMPATIBILITY SYSTEM (HLA) is HIGHLY involved in the LYME DISEASE, specifically the patients carrying the HLA DR molecules, it is even said that the presence of these molecules or ALLELES are involved in the pathogenicity of this disease and the triggering of AUTOIMMUNE DISEASES. In fact, there are studies showing the RESISTANCE TO SOME ANTIBIOTICS in relation to these HLA molecules.
There are HLA molecules that confer RESISTANCE TO THE DISEASE and OTHERS SUSCEPTIBILITY to the treatment, this would facilitate even more the behavior to follow with the patients; and I finish with this:
"... ALL PATIENT CARRIER OF LYME HAS TO HAVE A STUDY OF HISTOCOMPATIBILITY (HLA) ANTIGENS ..."
5.) LYME DISEASE AND GEOGRAPHICAL DISTRIBUTION:
===============================================
It is well known that the BORRELIA BURGDORFERI and its multiple SPECIES in the terrestrial globe, ARE DIFFERENT AS TO GEOGRAPHY, both in EUROPE and AMERICA. Well, I also tell you that there are studies showing that THE SPECIES OF BORRELIA in some ZONES such as EUROPE are sensitive to certain antibiotics, which in other areas of the continent show resistance, so that the GEOGRAPHICAL DISTRIBUTION AND SPECIES OF THE BORRELIA SPIROCHETE must be included in THE CODES.
6.) LYME DISEASE AND OPTICAL MICROSCOPY:
==========================================
The BORRELIA is an SPIROCHETE like the SYPHILIS, and the METHOD STANDART to detect the SYPHILIS IS OPTICAL MICROSCOPY, "DARK FIELD", then appeared other more sophisticated methods such as the VDRL and others. In the case of the BORRELIA, in the year 2.013 the professors LAANE and MYSTERUD, invented a simple method based on the fact that the BORRELIA, like the SYPHILIS TREPONEMA, could be "DETECTED" by means of a SIMPLE OPTICAL MICROSCOPE and that's how it was. They published the work (ref. 320), but were later discredited and dismissed by the scientific society including the CDC, claiming that the most effective methods were the laboratory ones, and today YET, many of the tests for LYME are negative and the BORRELIA "NAVIGATE" in the blood of patients. There I leave you the photo of BORRELIA AND BIOFILM and Professor LAANE.
If you read the previous review the CLASSIFICATION had been in the point No. 15: and here I put the continuation, it is important that you read the previous revision so that you can understand: THE CODES OF THE LYME DISEASE. CLICK here
15.) LYME LATENT DISEASE: UNSPECIFIED SYMPTOMS.
A.) INFECTION OF THE CENTRAL NERVOUS SYSTEM.
B.) HERPES SIMPLEX TYPE 1.
C.) DISEASES BY SPIROCHETES OF THE CENTRAL NERVOUS SYSTEM.
--- CONTINUATION--
16.) LYME DISEASE LATE STAGE: SYNDROME POST TREATMENT (PTLDS):
A.) FATIGUE.
B.) ARTHRALGIA.
C.) FIBROMYALGIA, MYALGIA.
D.) RADICULAR PAIN.
E.) MUSCULOSKELETAL PAIN.
F.) COGNITIVE DYSFUNTICON:
- DECREASED MEMORY.
- CONCETRATION PROBLEMS.
G.) PSYCHIATRICS CONDITIONS:
- DEPRESSION.
- SUICIDAL IDEATION.
- DEMENTIA.
H.) FACIAL PALSY.
I.) AUTOIMMUNE DISORDERS.
17.) LYME DISEASE ASSOCIATED TO OTHER DISEASES:
A.) MULTIPLE SCLEROSIS.
B.) PARKINSON.
C.) AUTOINMMUNE DISORDERS:
- REUMATOID ARTHRITIS.
- PSORIRIATIC ARTHRITIS.
- PERIPHERAL SPONDYLOARTHRITIS.
- POLYARTHRITIS.
18.) LYME DISEASE AND HLA (MAJOR SYSTEM OF HISTOCOMPATIBILITY) TRIGGER OTHER DISEASES:
A.) LYME ARTHRITIS: HLA-DRB1, (DRB1*0401, 0101, 0404, 0405, DRB5*0101, DRB1*0402, and 0102), DR11, DR4
19.) LYME DISEASE AND HLA DRB ANTIGENS (MAJOR SYSTEM OF HISTOCOMPATIBILITY) IS A MARKER FOR ANTIBIOTIC- REFRACTORY TRATMENT- and migth play a role in the pathogenesis os the disease.
A.) LYME ARTHRITIS.
20.) LYME DISEASE GEOGRAPHIC DISYTIBUTIONS, SPECIES OF BORRELIA LEADS TO ANTIBIOTICS SUSCESPTIBILITY.
A.) EUROPEAN LYME NEUROBORRELIOSIS: SUSCEPTIBILITY TO DOXYCYCLINE, PENICILLIN G, CEFTRIAXONE AND CEFOTAXIME.
21.) LYME DISEASE EARLY AND DELAYED JARISCH -HERXHEIMER REACCTION TO ANTIBIOTICS
A.) AMOXICILIN.
B.) DOXYCYCLINE.
C.) CEFTRIAXONE
22.) LYME DISEASE, SECUNDARY OR LATE STAGE: RESISTANT TO ANTIBIOTICS,
A.) DOXYCYCLINE.
B.) MINOCYCLINE.
C.) CEFTRIAXONE.
D.) AMOXICILIN.
E.) MITOMYCIN C.
F.) CEFUROXIME.
G.) DOXORUBICIN.
23.) LYME DISEASE AND NATURIST HERBS: oregano, cinnamon bark, and clove improve the disease.
24.) LYME DISEASE SUSCEPIBILITY TO COMBINED ANTIBIOTICS:
A.) DAPSONE + MINOCYCLINE+ CEFUROXIME+ AZYTHROMYCIN
B.) DAPSONE + MINOCYCLINE+ CEFUROXIME+ RIFAMPICIN
C.) DAPTOMYCIN + DOXYCYCLINE+ CEFUROXIME
D.) DAUNOMYCIN + DOXYCYLINE + CEFUROXIME
E.) DAPTOMYCIN+ CEFOPERAZONE+ DOXYCYCLINE.
F.) DAPTOMYCIN+ DOXYCYCLINE+ CLOFAZIMINE
G.) DATPOMICYN + (CEFOPERAZONE OR CARBENICILLIN)+ CLOFAZIMINE
I will remind you that the options DAPSONE + MINOCYCLINE + RIFAMPICIN and DAPSONE + CLOFAZIMINE + RIFAMPICIN are today classic treatments used in LEPROSY for more than 60 years and through which they have managed to reduce the incidence of this disease in the world today.
Practically the arrival of this TRIAD = DAPSONE + RIFAMPICIN + CLOFAZIMINE, in the 40s -50s years was the one who decreed the FINAL CLOSURE of the LEPROSERIES in the WORLD, read the stories here:
- THE LEPROSY IN CAPE WHITE. Clik Here
- LEPROSY ON THE ISLAND OF PROVIDENCIA. Click here
And as I told you before, do not miss the next issue of LYME, SYPHILIS AND LEPROSY, THE MISSING LINK.
Finally, I would like all the organizations and communities that fight against the LYME DISEASE, to send this CLASSIFICATION, CODES and BIBLIOGRAPHICAL REFERENCES to the World Health Organization (WHO), so that they can be updated regarding the serious problem that this disease represents in all the PLANET and that has been neglected for being aware of other health problems, much smaller, thinking perhaps that everything related to the word LYME, is an optical illusion that blinds them to such a severe problem.
Greetings to all.
Dr Jose Lapenta
"... Dedicated to all those LYME CARRIERS that society has forgotten ...or are in the oblivion..."
EDITORIAL ESPAÑOL
==================
Hola amigos de la red espero que muy bien en estas Navidades DERMAGIC EXPRESS les trae el segundo capítulo de LOS CODIGOS DE LA ENFERMEDAD DE LYME. En La revisión previa dije que faltaban algunos detalles que iba a aclarar en otra edición que ya estoy preparando y que se titulara LYME, SIFILIS Y LEPRA, EL ESLABON PERDIDO, pero sabía que la CLASIFICACION Y LOS CODIGOS DE LYME estaban INCOMPLETOS, y hoy te los pongo acá.
Había dicho que los CODIGOS a nivel DIGITAL o SOFTWARE están basados en una clasificación y que esta se hace en cuanto a la presentación clínica de la enfermedad y LOS REPORTES, PUBLICACIONES e INVESTIGACIONES CIENTIFICAS; y que la Organización Mundial de La Salud (OMS) , está TOTALMENTE desactualizada en cuanto a ello y POR LO TANTO no hay la suficiente cobertura de la ENFERMEDAD DE LYME Y SUS MULTIPLES MANIFESTACIONES CLINICAS, COMPLICACIONES y SINTOMAS derivados DE LA permanencia de la ESPIROQUETA BORRELIA en el cuerpo, las bases que sostienen estos hechos son:
1.) DIFICULTAD PARA HACER EL DIAGNOSTICO:
2.) RESISTENCIA AL TRATAMIENTO CONVENCIONAL:
3.) LA FALTA DE MODERNIZACION DE LOS CODIGOS PARA LA ENFERMEDAD DE LYME.
Y hoy te traigo otras REFRENCIAS BIBLIOGRAFICAS que completarían una CLASIFICACION que a mi modo de ver AMPLIARIA TOTALMENTE la asistencia a MILES DE PACIENTES portadores de LYME que simplemente no "APARECEN EN EL SISTEMA" pues los CODIGOS no existen. Hoy le agrego un 4to y 5to aspecto:
4.) ENFERMEDAD DE LYME Y ANTIGENOS DE HISTOCOMPATIBILIDAD: (HLA)
===============================================================
Es de resaltar en estos datos que hoy te voy a colocar que el SISTEMA MAYOR DE HISTOCOMPATIBILIDAD (HLA) está ALTAMENTE involucrado en la ENFERMEDAD DE LYME, específicamente los pacientes portadores de las moléculas HLA DR, incluso se habla de que la presencia de estas moléculas o ALELOS están involucrados en la patogenicidad de esta enfermedad y el desencadenamiento de ENFERMEDADES AUTOINMUNES. De hecho hay estudios donde se demuestra LA RESISTENCIA A ALGUNOS ANTIBIOTICOS en relación a estas moléculas HLA.
Hay moléculas HLA que confieren RESISTENCIA A LA ENFERMEDAD y OTRAS SUSCEPTIBILIDAD al tratamiento, esto facilitaría aun más la conducta a seguir con los pacientes; y finalizo con esto:
"...TODO PACIENTE PORTADOR DE LYME TIENE QUE TENER UN ESTUDIO DE ANTIGENOS DE HISTOCOMPATIBILIDAD (HLA)..."
5.) ENFERMEDAD DE LYME Y DISTRIBUCION GEOGRAFICA:
================================================
Bien es sabido que la BORRELIA BURDORGFERI y sus múltiples ESPECIES en el globo terráqueo, SON DIFERENTES EN CUANTO A LA GEOGRAFIA, tanto en EUROPA como AMERICA. Pues también te digo que hay estudios donde se demuestra que LAS ESPECIES DE BORRELIA en algunas ZONAS como EUROPA son sensibles a determinados antibióticos, donde en otras áreas del continente muestran resistencia, DE MODO que la DISTRIBUCION GEOGRAFICA Y ESPECIES DE LA ESPIROQUETA BORRELIA deben FIGURAR EN LOS CODIGOS.
6.) ENFERMEDAD DE LYME Y MICROSCOPIA OPTICA:
============================================
La BORRELIA es una ESPIROQUETA al igual que la SIFILIS, y el METODO ESTANDART para detectar la SIFILIS ES LA MICROSCOPIA OPTICA, "CAMPO OSCURO", luego aparecieron otros métodos más sofisticados como el VDRL y otros más. En el caso de la BORRELIA, en el año 2.013 los profesores LAANE y MYSTERUD, idearon un método sencillo basado en el hecho de que la BORRELIA al igual que la SIFILIS, TREPONEMA podía "DETECTARSE" por medio de una SIMPLE MICROSCOPIA OPTICA y así fue. Publicaron el trabajo (ref. 320), pero fueron posteriormente desacreditados y desechados por la sociedad científica incluyendo el CDC, alegando que los métodos más eficaces eran los de laboratorio, y hoy día TODAVIA, muchas de las pruebas para LYME dan negativo y la BORRELIA "NAVEGA" en la sangre de los pacientes. Allí les dejo la foto de la BORRELIA Y BIOFILM y el profesor LAANE.
Si lees la revisión previa la CLASIFICACION había quedado en el punto No. 15: y acá te pongo la continuación, es importante que leas la revisión previa para que puedas entender: LOS CODIGOS DE LA ENFERMEDAD DE LYME. Click aqui
15.) ENFERMEDAD DE LYME LATENTE: SINTOMAS INESPECIFICOS.
A.) INFECCION DEL SISTEMA NERVIOSO CENTRAL.
B.) HERPES SIMPLE TIPO 1.
C.) ENFERMEDADES POR ESPIROQUETAS DEL SISTEMA NERVIOSO CENTRAL.
- CONTINUACION -
16.) ENFERMEDAD DE LYME, ETAPA TARDIA: SÍNDROME POST TRATAMIENTO (PTLDS):
A.) FATIGA.
B.) ARTRALGIA.
C.) FIBROMIALGIA, MIALGIA.
D.) DOLOR RADICULAR.
E.) DOLOR MUSCULOESQUELÉTICO.
F.) DISFUNTICON COGNITIVA:
- DISMINUCIÓN DE LA MEMORIA
- PROBLEMAS DE CONCENTRACIÓN.
G.) CONDICIONES DE PSIQUIATRICAS:
- DEPRESIÓN.
- IDEACIÓN SUICIDA.
- DEMENCIA.
H.) PARÁLISIS FACIAL.
I.) TRASTORNOS AUTOINMUNES.
17.) ENFERMEDAD DE LYME ASOCIADA A OTRAS ENFERMEDADES:
A.) ESCLEROSIS MÚLTIPLE.
B.) PARKINSON.
C.) TRASTORNOS AUTOINMUNES:
- ARTRITIS REUMATOIDE.
- ARTRITIS PSORIÁTICA.
- ESPONDILOARTRITIS PERIFÉRICA.
- POLIARTRITIS.
18.) ENFERMEDAD DE LYME Y HLA (SISTEMA MAYOR DE HISTOCOMPATIBILIDAD) DESENCADENAN OTRAS ENFERMEDADES:
A.) ARTRITIS DE LYME: HLA-DRB1, (DRB1 * 0401, 0101, 0404, 0405, DRB5 * 0101, DRB1 * 0402 y 0102), DR11, DR4
19.) ENFERMEDAD LYME Y LOS ANTÍGENOS HLA DR-B (SISTEMA MAYOR DE HISTOCOMPATIBILIDAD) ES UN MARCADOR PARA TRATAMIENTO ANTIBIÓTICO-REFRACTARIO, y pueden desempeñar un papel en la patogénesis de la enfermedad.
A.) LYME ARTRITIS.
20.) ENFERMEDAD DE LYME Y DISTRIBUCION GEOGRÁFICAS DE LAS ESPECIES DE BORRELIA Y SUSCEPTIBILIDAD A ANTIBIÓTICOS.
A.) NEUROBORRELIOSIS DE LYME EN EUROPA: SUSCEPTIBILIDAD A LA DOXICICLINA, PENICILINA G, CEFTRIAXONA Y CEFOTAXIMA.
21.) ENFERMEDAD DE LYME: REACCIÓN DE JARISCH - HERXHEIMER TEMPRANA Y TARDIA A ANTIBIÓTICOS
A.) AMOXICILINA.
B.) DOXICICLINA
C.) CEFTRIAXONA.
22.) ENFERMEDAD DE LYME, ETAPA SECUNDARIA O TARDÍA: RESISTENTE A LOS ANTIBIÓTICOS,
A.) DOXICICLINA.
B.) MINOCICLINA.
C.) CEFTRIAXONA.
D.) AMOXICILINA.
E.) MITOMICINA C.
F.) CEFUROXIMA.
G.) DOXORUBICINA.
23.) ENFERMEDAD DE LYME Y HIERBAS NATURISTAS: el orégano, la corteza de canela y el clavo mejoran la enfermedad.
24.) ENFERMEDAD LYME Y SUSCEPTIBILIDAD A ANTIBIÓTICOS COMBINADOS:
A.) DAPSONA + MINOCICLINA + CEFUROXIMA + AZYTROMICINA
B.) DAPSONA + MINOCICLINA + CEFUROXIMA + RIFAMPICINA
C.) DAPTOMICINA + DOXICICLINA + CEFUROXIMA
D.) DAUNOMICINA + DOXICICLINA + CEFUROXIMA
E.) DAPTOMICINA + CEFOPERAZONA + DOXICICLINA.
F.) DAPTOMICINA + DOXICICLINA + CLOFAZIMINE
G.) DATPOMICINA + (CEFOPERAZONA O CARBENICILINA) + CLOFAZIMINE
Les voy a recordar que las opciones DAPSONA + MINOCICLINA + RIFAMPICINA y DAPSONA + CLOFAZIMINE + RIFAMPICINA son hoy tratamientos clásicos utilizados en la LEPRA durante más de 60 años y que han logrado reducir la incidencia de esta enfermedad en el mundo hoy día.
Prácticamente la llegada de esta TRIADA= DAPSONA+ RIFAMPICINA+ CLOFAZIMINE, en los años 40-50 fue quien decreto el CIERRE DEFINITIVO de las LEPROSERIAS en el MUNDO, léase las historias aquí:
- LA LEPRA EN CABO BLANCO. Click aqui
- LEPRA EN LA ISLA DE PROVIDENCIA. Click aqui
Y como te dije anteriormente no te pierdas la próxima edición LYME, SIFILIS Y LEPRA, EL ESLABON PERDIDO.
Por ultimo quisiera que todas las organizaciones y comunidades que luchan contra LA ENFERMEDA DE LYME, envien esta CLASIFICACION, CODIGOS Y REFERENCIAS BIBLIOGRAFICAS a la Organizacion Mundial de la Salud (OMS), para que se actualicen en cuanto al grave problema que representa esta enfermedad en todo el PLANETA y que ha sido descuidada por estar pendientes de otros problemas de salud, mucho menores, pensando quiza que todo lo relacionado con la palabra LYME, es una ilusion optica que les ciega la vista a tan severo problema.
Saludos a Todos
Dr. José Lapenta
"...Dedicado a todos aquellos PORTADORES DE LYME que la sociedad tiene en el olvido...."
=========================================================
REFERENCIAS BIBLIOGRAFICAS / BIBLIOGRAPHICAL REFERENCES
=========================================================
282.) Effects of intravenous ketamine in a patient with post-treatment Lyme disease syndrome. Int Med Case Rep J. 2017 Aug 18;10:305-308. doi: 10.2147/IMCRJ.S137975. eCollection 2017. [PUBMED] Hanna AF1, Abraham B1, Hanna A1, Smith AJ1.
283.) Update of the Swiss guidelines on post-treatment Lyme disease syndrome. Swiss Med Wkly. 2016 Dec 5;146:w14353. doi: 10.4414/smw.2016.14353. eCollection 2016. [PUBMED] Nemeth J1, Bernasconi E2, Heininger U3, Abbas M4, Nadal D5, Strahm C6, Erb S7, Zimmerli S8, Furrer H8, Delaloye J9, Kuntzer T10, Altpeter E11, Sturzenegger M12, Weber R1,
284.) Lyme disease and post-treatment Lyme disease syndrome: the neglected disease in our own backyard.Public Health. 2014 Sep;128(9):784-91. doi: 10.1016/j.puhe.2014.06.016. Epub 2014 Sep 9. [PUBMED]
285.) Post-Lyme borreliosis syndrome: a meta-analysis of reported symptoms.Int J Epidemiol. 2005 Dec;34(6):1340-5. Epub 2005 Jul 22. [PUBMED] Cairns V1, Godwin J.
286.) Post-Lyme disease syndrome. Reumatologia.2015;53(1):46-8.doi: 10.5114/ reum. 2015.50557. Epub 2015 Apr 10.[PUBMED] Scieszka J1, Dabek J2, Cieslik P1.
287.) Comparison of post-Lyme Borreliosis symptoms in erythema migrans patients with positive and negative Borrelia burgdorferi sensu lato skin culture.Vector Borne Zoonotic Dis. 2011 Jul;11(7):883-9. doi: 10.1089/vbz.2010.0018. Epub 2010 Nov 17. [PUBMED] Stupica D1, Lusa L, Cerar T, Ružic-Sabljic E, Strle F.
288.) Long-term Assessment of Post-Treatment Symptoms in Patients With Culture-Confirmed Early Lyme Disease. Clin Infect Dis. 2015 Dec 15;61(12):1800-6. doi: 10.1093/cid/civ735. Epub 2015 Sep 18. [PUBMED] Weitzner E1, McKenna D1, Nowakowski J1, Scavarda C1, Dornbush R2, Bittker S1, Cooper D1, Nadelman RB1, Visintainer P3, Schwartz I4, Wormser GP1.
289.) Chronic Lyme borreliosis at the root of multiple sclerosis--is a cure with antibiotics attainable? Med Hypotheses. 2005;64(3):438-48. [PUBMED] Fritzsche M1.
290.) The Data as It Is, and the Nature of Neurocognitive Difficulties in Post-Treatment Lyme Disease. Arch Clin Neuropsychol. 2017 Dec 13. doi: 10.1093/arclin/acx121. [Epub ahead of print] [PUBMED] Keilp JG1, Fallon BA2.
291.) Clinical and neurocognitive features of the post Lyme syndrome. J Rheumatol. 1996 Aug;23(8):1392-7. [PUBMED] Bujak DI1, Weinstein A, Dornbush RL.
292.) Terrestrial distribution of the Lyme borreliosis agent Borrelia burgdorferi sensu lato in East Asia. Jpn J Infect Dis. 2004 Dec;57(6):229-35. [PUBMED] Masuzawa T1.
293.) Variable manifestations, diverse seroreactivity and post-treatment persistence in non-human primates exposed to Borrelia burgdorferi by tick feeding. PLoS One. 2017 Dec 13;12(12):e0189071. doi: 10.1371/journal.pone.0189071. eCollection 2017. [PUBMED]
Embers ME1, Hasenkampf NR1, Jacobs MB1, Tardo AC1, Doyle-Meyers LA2, Philipp MT1, Hodzic E3.
294.) Persistence of Borrelia burgdorferi in rhesus macaques following antibiotic treatment of disseminated infection. PLoS One. 2012;7(1):e29914. doi: 10.1371/journal.pone.0029914. Epub 2012 Jan 11. [PUBMED] Embers ME1, Barthold SW, Borda JT, Bowers L, Doyle L, Hodzic E, Jacobs MB, Hasenkampf NR, Martin DS, Narasimhan S, Phillippi-Falkenstein KM, Purcell JE, Ratterree MS, Philipp MT.
295.) Unique expression of chronic Lyme disease and Jarisch-Herxheimer reaction to doxycycline therapy in a young adult. BMJ Case Rep. 2016 Jul 20;2016. pii: bcr2013009433. doi: 10.1136/bcr-2013-009433. [PUBMED] Haney C1, Nahata MC2.
296.) Lyme disease complicated by the Jarisch-Herxheimer reaction. J Emerg Med. 1998 May-Jun;16(3):437-8.[PUBMED] Maloy AL1, Black RD, Segurola RJ Jr.
297.) Delayed onset of the Jarisch-Herxheimer reaction in doxycycline-treated disease: a case report and review of its histopathology and implications for pathogenesis. Am J Dermatopathol. 2015 Jun;37(6):e68-74. doi: 10.1097/DAD.0000000000000093. [PUBMED] Kadam P1, Gregory NA, Zelger B, Carlson JA.
298.) Transient worsening of optic neuropathy as a sequela of the Jarisch-Herxheimer reaction in the treatment of Lyme disease. J Neuroophthalmol. 1994 Jun;14(2):77-80. [PUBMED] Strominger MB1, Slamovits TL, Herskovitz S, Lipton RB.
299.) Successful desensitisation to ceftriaxone in a patient with doxycicline resistant Lyme disease. Erratum in Allergol Immunopathol (Madr). 2009 Jul-Aug;37(4):222.[PUBMED] Rodrigues J, Cruz LG, Botelho C, Rio E, Castel-Branco MG.
300.) Ceftriaxone Pulse Dosing Fails to Eradicate Biofilm-Like Microcolony B. burgdorferi Persisters Which Are Sterilized by Daptomycin/ Doxycycline/Cefuroxime without Pulse Dosing. Front Microbiol. 2016 Nov 4;7:1744. eCollection 2016. [PUBMED] Feng J1, Zhang S1, Shi W1, Zhang Y1.
301.) Antibiotics for the neurological complications of Lyme disease. Cochrane Database Syst Rev. 2016 Dec 8;12:CD006978. doi: 10.1002/14651858.CD006978.pub2. [PUBMED] Cadavid D1, Auwaerter PG2, Rumbaugh J3, Gelderblom H4.
302.) Lyme borreliosis in Slovenia. Zentralbl Bakteriol. 1999 Dec;289(5-7):643-52. [PUBMED] Strle F1.
303.) Immunogenic HLA-DR-Presented Self-Peptides Identified Directly from Clinical Samples of Synovial Tissue, Synovial Fluid, or Peripheral Blood in Patients with Rheumatoid Arthritis or Lyme Arthritis. J Proteome Res. 2017 Jan 6;16(1):122-136. doi: 10.1021/acs.jproteome.6b00386. Epub 2016 Nov 7. [PUBMED] Wang Q1, Drouin EE2, Yao C1, Zhang J1,3, Huang Y1, Leon DR1, Steere AC2, Costello CE1.
304.) Autoimmune Arthritides, Rheumatoid Arthritis, Psoriatic Arthritis, or Peripheral Spondyloarthritis Following Lyme Disease. Arthritis Rheumatol. 2017 Jan;69(1):194-202. doi: 10.1002/art.39866. [PUBMED] Arvikar SL1, Crowley JT1, Sulka KB1, Steere AC1.
305.) T-Helper 17 Cell Cytokine Responses in Lyme Disease Correlate With Borrelia burgdorferi Antibodies During Early Infection and With Autoantibodies Late in the Illness in Patients With Antibiotic-Refractory Lyme Arthritis. Clin Infect Dis. 2017 Apr 1;64(7):930-938. doi: 10.1093/cid/cix002. [PUBMED] Strle K1, Sulka KB1, Pianta A1, Crowley JT1, Arvikar SL1, Anselmo A2, Sadreyev R2, Steere AC1.
306.) Serum reactivity against Borrelia burgdorferi OspA in patients with rheumatoid arthritis. Clin Vaccine Immunol. 2007 Nov;14(11):1437-41. Epub 2007 Sep 19. [PUBMED] Hsieh YF1, Liu HW, Hsu TC, Wei JC, Shih CM, Krause PJ, Tsay GJ.
307.) HLA type and immune response to Borrelia burgdorferi outer surface protein a in people in
whom arthritis developed after Lyme disease vaccination. Arthritis Rheum. 2009 Apr;60(4):1179-86. doi: 10.1002/art.24418.[PUBMED]Ball R1, Shadomy SV, Meyer A, Huber BT, Leffell MS, Zachary A, Belotto M, Hilton E, Bryant-Genevier M, Schriefer ME, Miller FW, Braun MM.
308.) HLA-DR alleles determine responsiveness to Borrelia burgdorferi antigens in a mouse model of self-perpetuating arthritis. Arthritis Rheum. 2009 Dec;60(12):3831-40. doi: 10.1002/art.25005. [PUBMED] Iliopoulou BP1, Guerau-de-Arellano M, Huber BT.
309.) Antibiotic-refractory Lyme arthritis is associated with HLA-DR molecules that bind a Borrelia burgdorferi peptide. J Exp Med. 2006 Apr 17;203(4):961-71. Epub 2006 Apr 3. [PUBMED] Steere AC1, Klitz W, Drouin EE, Falk BA, Kwok WW, Nepom GT, Baxter-Lowe LA.
310.) Association of antibiotic treatment-resistant Lyme arthritis with T cell responses to dominant epitopes of outer surface protein A of Borrelia burgdorferi. Arthritis Rheum. 1999 Sep;42(9):1813-22. [PUBMED] Chen J1, Field JA, Glickstein L, Molloy PJ, Huber BT, Steere AC.
311.) Associations of HLA DR and DQ molecules with Lyme borreliosis in Latvian patients. BMC Res Notes. 2012 Aug 14;5:438. doi: 10.1186/1756-0500-5-438. [PUBMED] Kovalchuka L1, Eglite J, Lucenko I, Zalite M, Viksna L, Krumina A.
312.) Immunogenetic Markers Definition in Latvian Patients with Lyme Borreliosis and Lyme Neuroborreliosis. Int J Environ Res Public Health. 2016 Dec 1;13(12). pii: E1194. [PUBMED] Kovalchuka L1, Cvetkova S2, Trofimova J3, Eglite J4, Gintere S5, Lucenko I6, Oczko-Grzesik B7, Viksna L8, Krumina A9,10.
313.) Serological Evidence of Borrelia Burgdorferi Infection in Mexican Patients with Facial Palsy. Rev Invest Clin. 2017 Nov-Dec;69(6):344-348. doi: 10.24875/RIC.17002344. [PUBMED] Gordillo-Pérez G1, García-Juárez I1, Solórzano-Santos F2, Corrales-Zúñiga L3, Muñoz-Hernández O2, Torres-López J1.
314.) Selective Essential Oils from Spice or Culinary Herbs Have High Activity against Stationary Phase and Biofilm Borrelia burgdorferi. Front Med (Lausanne). 2017 Oct 11;4:169. doi: 10.3389/fmed.2017.00169. eCollection 2017. [PUBMED] Feng J1, Zhang S1, Shi W1, Zubcevik N2, Miklossy J3, Zhang Y1.
315.) Eradication of Biofilm-Like Microcolony Structures of Borrelia burgdorferi by Daunomycin and Daptomycin but not Mitomycin C in Combination with Doxycycline and Cefuroxime. Front Microbiol. 2016 Feb 10;7:62. doi: 10.3389/fmicb.2016.00062. eCollection 2016. [PUBMED] Feng J1, Weitner M1, Shi W1, Zhang S1, Zhang Y1.
316.) Drug combinations against Borrelia burgdorferi persisters in vitro: eradication achieved by using daptomycin, cefoperazone and doxycycline. PLoS One. 2015 Mar 25;10(3):e0117207. doi: 10.1371/journal.pone.0117207. eCollection 2015. [PUBMED] Feng J1, Auwaerter PG2, Zhang Y1.
317.) Activity of Sulfa Drugs and Their Combinations against Stationary Phase B. burgdorferi In Vitro. Antibiotics (Basel). 2017 Mar 22;6(1). pii: E10. doi: 10.3390/antibiotics6010010. [PUBMED] Feng J1, Zhang S2, Shi W3, Zhang Y4.
318.) Lyme neuroborreliosis and dementia. J Alzheimers Dis. 2014;41(4):1087-93. doi: 10.3233/JAD-130446. [PUBMED]Blanc F1, Philippi N1, Cretin B1, Kleitz C2, Berly L2, Jung B1, Kremer S3, Namer IJ4, Sellal F5, Jaulhac B6, de Seze J7.
319.) Distribution and presentation of Lyme borreliosis in Scotland - analysis of data from a national testing laboratory. J R Coll Physicians Edinb. 2015;45(3):196-200. doi: 10.4997/JRCPE.2015.304. [PUBMED] Mavin S1, Watson EJ, Evans R.
320.) A simple method for the detection of live Borrelia spirochaetes in human blood using classical microscopy techniques. Morten Motzfeldt Laane, Ivar Mysterud. Published 2013. Semantic Sholar. Source: https://www.semanticscholar.org/paper/A-simple-method-for-the-detection-of-live-Borrelia-Laane-Mysterud/4f6251e40f196b094905d84e87b8b6fe8d1d1636
Suppression of Microscopy for Lyme Diagnostics – Professor Laane |
Source: https://madisonarealymesupportgroup.com/
=====================================================================
